OTCMKTS:BVNRY BAVARIAN NORDIC/S Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding BAVARIAN NORDIC/S Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $11.00 0.00 (0.00 %) (As of 09/25/2020 12:00 AM ET) Add Compare Share Today's Range$11.00Now: $11.00▼$11.0050-Day Range$9.61MA: $10.89▼$12.0052-Week Range$5.04Now: $11.00▼$12.25VolumeN/AAverage Volume397 shsMarket Capitalization$1.93 billionP/E Ratio21.57Dividend YieldN/ABeta1.63 ProfileChartCompetitorsEarningsHeadlinesShort InterestSocial Media Bavarian Nordic A/S, a biotechnology company, develops, manufactures, and commercializes a portfolio of cancer immunotherapies and vaccines for infectious diseases. The company markets non-replicating smallpox vaccine under the IMVAMUNE and IMVANEX names. It is also developing MVA-BN RSV, which is in Phase II clinical trials development stage for the prevention of respiratory syncytial virus; MVA-BN Filo that is in Phase III clinical trials for the treatment of Ebola and Marburg; and MVA-BN HPV that is in Phase I/IIa clinical trials to treat human papillomavirus. In addition, the company develops MVA-BN HIV, a preclinical stage human immunodeficiency virus (HIV) vaccine candidate; MVA-BN HBV, a preclinical stage hepatitis B vaccine candidate; CV301 that is in various clinical trials for the treatment of bladder, colorecta, and pancreatic and colorectal cancers; and MVA-BN Brachyury that is in Phase II clinical trials for the treatment of chordoma and other metastatic cancers. It has license agreements with National Cancer Institute and Public Health Service. The company operates in the United States, the Netherlands, Canada, and internationally. Bavarian Nordic A/S was founded in 1994 and is based in Kvistgård, Denmark.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for BAVARIAN NORDIC/S. Previous Next 2.7 Community Rank Outperform VotesBAVARIAN NORDIC/S has received 181 “outperform” votes. (Add your “outperform” vote.)Underperform VotesBAVARIAN NORDIC/S has received 153 “underperform” votes. (Add your “underperform” vote.)Community SentimentBAVARIAN NORDIC/S has received 54.19% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about BAVARIAN NORDIC/S and other stocks. Vote “Outperform” if you believe BVNRY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BVNRY will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldBAVARIAN NORDIC/S does not currently pay a dividend.Dividend GrowthBAVARIAN NORDIC/S does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BAVARIAN NORDIC/S insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for BAVARIAN NORDIC/S are expected to decrease by -61.82% in the coming year, from $0.55 to $0.21 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BAVARIAN NORDIC/S is 21.57, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.37.Price to Earnings Ratio vs. SectorThe P/E ratio of BAVARIAN NORDIC/S is 21.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.55.Price to Book Value per Share RatioBAVARIAN NORDIC/S has a P/B Ratio of 3.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.67 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BVNRY Previous Symbol CUSIPN/A CIKN/A Webwww.bavarian-nordic.com Phone45-3326-8383Debt Debt-to-Equity Ratio0.09 Current Ratio3.93 Quick Ratio3.72Price-To-Earnings Trailing P/E Ratio21.57 Forward P/E Ratio20.00 P/E GrowthN/A Sales & Book Value Annual Sales$99.33 million Price / Sales19.39 Cash FlowN/A Price / Cash FlowN/A Book Value$2.88 per share Price / Book3.82Profitability EPS (Most Recent Fiscal Year)($0.53) Net Income$-51,980,000.00 Net Margins31.95% Return on Equity13.54% Return on Assets6.85%Miscellaneous Employees419 Outstanding Shares175,070,000Market Cap$1.93 billion Next Earnings Date11/5/2020 (Estimated) OptionableNot Optionable $11.00 0.00 (0.00 %) (As of 09/25/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive BVNRY News and Ratings via Email Sign-up to receive the latest news and ratings for BVNRY and its competitors with MarketBeat's FREE daily newsletter. BAVARIAN NORDIC/S (OTCMKTS:BVNRY) Frequently Asked Questions How has BAVARIAN NORDIC/S's stock price been impacted by Coronavirus? BAVARIAN NORDIC/S's stock was trading at $9.00 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, BVNRY shares have increased by 22.2% and is now trading at $11.00. View which stocks have been most impacted by COVID-19. When is BAVARIAN NORDIC/S's next earnings date? BAVARIAN NORDIC/S is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for BAVARIAN NORDIC/S. How were BAVARIAN NORDIC/S's earnings last quarter? BAVARIAN NORDIC/S (OTCMKTS:BVNRY) posted its earnings results on Wednesday, August, 26th. The company reported $0.11 EPS for the quarter, topping the consensus estimate of ($0.10) by $0.21. The company had revenue of $103.26 million for the quarter, compared to analysts' expectations of $32.40 million. BAVARIAN NORDIC/S had a return on equity of 13.54% and a net margin of 31.95%. View BAVARIAN NORDIC/S's earnings history. Are investors shorting BAVARIAN NORDIC/S? BAVARIAN NORDIC/S saw a increase in short interest in August. As of August 31st, there was short interest totaling 4,900 shares, an increase of 172.2% from the August 15th total of 1,800 shares. Based on an average daily volume of 2,300 shares, the short-interest ratio is presently 2.1 days. View BAVARIAN NORDIC/S's Short Interest. Who are some of BAVARIAN NORDIC/S's key competitors? Some companies that are related to BAVARIAN NORDIC/S include Repligen (RGEN), Novavax (NVAX), Adaptive Biotechnologies (ADPT), Acceleron Pharma (XLRN), Momenta Pharmaceuticals (MNTA), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Ablynx (ABLYF), bluebird bio (BLUE), Denali Therapeutics (DNLI), Halozyme Therapeutics (HALO) and Relay Therapeutics (RLAY). View all competitors. Who are BAVARIAN NORDIC/S's key executives? BAVARIAN NORDIC/S's management team includes the following people: Dr. Paul Chaplin, CEO & Pres (Age 52)Mr. Henrik Juuel, CFO & Exec. VP (Age 54)Mr. Henrik Birk, COO & Exec. VP (Age 45)Dr. Tommi Kainu, Exec. VP & Chief Bus. Officer (Age 46)Dr. Christopher R. Heery, Chief Medical Officer What is BAVARIAN NORDIC/S's stock symbol? BAVARIAN NORDIC/S trades on the OTCMKTS under the ticker symbol "BVNRY." How do I buy shares of BAVARIAN NORDIC/S? Shares of BVNRY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is BAVARIAN NORDIC/S's stock price today? One share of BVNRY stock can currently be purchased for approximately $11.00. How big of a company is BAVARIAN NORDIC/S? BAVARIAN NORDIC/S has a market capitalization of $1.93 billion and generates $99.33 million in revenue each year. The company earns $-51,980,000.00 in net income (profit) each year or ($0.53) on an earnings per share basis. BAVARIAN NORDIC/S employs 419 workers across the globe. What is BAVARIAN NORDIC/S's official website? The official website for BAVARIAN NORDIC/S is www.bavarian-nordic.com. How can I contact BAVARIAN NORDIC/S? BAVARIAN NORDIC/S's mailing address is Hejreskovvej 10A, Kvistgaard G7, 3490. The company can be reached via phone at 45-3326-8383 or via email at [email protected] This page was last updated on 9/25/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
